Biosimilar use in the United States: An analysis of filgrastim and infliximab

被引：0
|
作者：
Dutcher, Sarah K. [1 ]
Eworuke, Efe [1 ]
Fazio-Eynullayeva, Elnara [2 ,3 ]
Dee, Elizabeth [2 ,3 ]
Nguyen, Michael D. [1 ]
Panozzo, Catherine A. [2 ,3 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
978
引用
收藏
页码：475 / 475
页数：1
相关论文
共 50 条
  • [1] Filgrastim-sndz debuts as the frst biosimilar approved in United States
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (12): : 420 - 422
  • [2] Effect of biosimilar market entry on cost of biologics in the United States: The case of filgrastim
    Mouslim, Morgane
    Alexander, Caleb
    Segal, Jodi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 24 - 24
  • [3] Effect of biosimilar market entry on utilization of biologics in the united states: the case of filgrastim
    Mouslim, Morgane
    Segal, Jodi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 646 - 647
  • [4] Biosimilar infliximab use in paediatric IBD
    Richmond, Lisa
    Curtis, Lee
    Garrick, Victoria
    Rogers, Pam
    Wilson, Michelle
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Wilson, David C.
    Russell, Richard K.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2018, 103 (01) : 89 - 91
  • [5] Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
    Qureshi, Zaina P.
    Nagai, Sumimasa
    Bennett, Charles L.
    JAMA ONCOLOGY, 2019, 5 (03) : 297 - 298
  • [6] Trends in the utilization of short-acting filgrastim following the United States market launch of the first biosimilar
    Jazowski, Shelley
    Dusetzina, Stacie
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 482 - 482
  • [7] Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
    Hussaini, S. M. Qasim
    Gupta, Arjun
    Anderson, Kelly E.
    Ballreich, Jeromie M.
    Nicholas, Lauren Hersch
    Alexander, G. Caleb
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [8] Filgrastim-Biosimilar
    best practice onkologie, 2010, 5 (6) : 34 - 34
  • [9] Zarxio - A Filgrastim Biosimilar
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1490): : 34 - 35
  • [10] Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019
    Liu, Angela
    Xuan, Andrew
    Socal, Mariana
    Anderson, Gerard
    Anderson, Kelly E.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (01): : 15 - 21
12345